Subsensitivity of bronchodilator and systemic beta 2 adrenoceptor responses after regular twice daily treatment with eformoterol dry powder in asthmatic patients

Newnham, D M; Grove, A; McDevitt, D G; Lipworth, B J
May 1995
Thorax;May1995, Vol. 50 Issue 5, p497
Academic Journal
No abstract available.


Related Articles

  • Responses to a beta-agonist after salmeterol treatment. Pinkowish, Mary Desmond // Patient Care;9/30/1995, Vol. 29 Issue 15, p98 

    Reports briefly on the study to assess the effects of salmeterol on the acute effects of the bronchodilator salbutamol by researchers at the University of Dundee, Scotland. Original publication titled,` Bronchodilator subsensitivity to salbutamol after twice daily salmeterol in asthmatic...

  • Tolerance to bronchodilation during treatment with long-acting beta-agonists, a randomised controlled trial. Haney, Sarah; Hancox, Robert J. // Respiratory Research;2005, Vol. 6, p107 

    Background: Regular use of beta-agonists leads to tolerance to their bronchodilator effects. This can be demonstrated by measuring the response to beta-agonist following bronchoconstriction using methacholine. However most studies have demonstrated tolerance after a period of betaagonist...

  • Overcoming beta-agonist tolerance: high dose salbutamol and ipratropium bromide. Two randomised controlled trials. Haney, Sarah; Hancox, Robert J. // Respiratory Research;2007, Vol. 8, p19 

    Background: Asthmatics treated with long-acting beta-agonists have a reduced bronchodilator response to moderate doses of inhaled short acting beta-agonists during acute bronchoconstriction. It is not known if the response to higher doses of nebulised beta-agonists or other bronchodilators is...

  • Budesonide/Formoterol: A Review of its Use as Maintenance and Reliever Inhalation Therapy in Asthma. McCormack, Paul L.; Lyseng-Williamson, Katherine A. // Drugs;2007, Vol. 67 Issue 16, p2407 

    The use of combination budesonide/formoterol dry powder inhaler (Symbicort® Turbuhaler®) for both daily maintenance therapy and as-needed relief of breakthrough symptoms using a single inhaler is a new approach to asthma management that is indicated in patients with persistent asthma not...

  • Ventide.  // Royal Society of Medicine: Medicines;2002, p560 

    This article presents information on Ventide drug. The drug is a proprietary, prescription-only compound preparation of the corticosteroid beclometasone dipropionate and the sympathomimetic, bronchodilator and beta-receptor stimulant salbutamol. It can be used as a treatment for the symptomatic...

  • Ventodisks.  // Royal Society of Medicine: Medicines;2002, p560 

    This article presents information on Ventodisks drug. The drug is a proprietary, prescription-only preparation of the beta-receptor stimulant salbutamol. It can be used as a bronchodilator in reversible obstructive airways disease, such as in anti-asthmatic treatment in severe acute asthma. It...

  • Long-Acting Beta-Agonists and their Association with Inhaled Corticosteroids in COPD. Fuso, L.; Mores, N.; Valente, S.; Malerba, M.; Montuschi, P. // Current Medicinal Chemistry;Apr2013, Vol. 20 Issue 10-13, p1477 

    Inhaled bronchodilators, including beta2-agonists and antimuscaric receptor antagonists, are the mainstay of pharmacotherapy in chronic obstructive pulmonary disease (COPD). The short-acting beta2-agonists, including salbutamol, and fenoterol, have a rapid onset of action, a bronchodilating...

  • Arformoterol: (R,R)-Eformoterol, (R,R)-Formoterol, Arformoterol Tartrate, Eformoterol-Sepracor, Formoterol-Sepracor, R,R-Eformoterol, R,R-Formoterol. Adis International Limited // Drugs in R&D;2004, Vol. 5 Issue 1, p25 

    Sepracor in the US is developing arformoterol [R,R-formoterol], a single isomer form of the β[sub 2]-adrenoceptor agonist formoterol [eformoterol]. This isomer contains two chiral centres and is being developed as an inhaled preparation for the treatment of respiratory disorders. Sepracor...

  • Salmeterol/Fluticasone Propionate: A Review of its Use in the Treatment of Chronic Obstructive Pulmonary Disease. Keating, Gillian M.; McCormack, Paul L. // Drugs;2007, Vol. 67 Issue 16, p2383 

    Salmeterol/fluticasone propionate (Seretide®, Advair®, Viani®) administered using a multidose dry powder inhaler (Diskus®, Accuhaler®) is approved for use in the treatment of chronic obstructive pulmonary disease (COPD) in numerous countries. Salmeterol/fluticasone propionate...

  • Bronchodilator effect of single-dose formoterol administered by pressurized metered-dose inhaler in children with asthma aged 6 to <12 years receiving budesonide. Berger, William E.; Gillen, Michael; Eckerwall, Göran; Uryniak, Tom; Trudo, Frank J.; Lampl, Kathy L. // Allergy & Asthma Proceedings;Mar/Apr2014, Vol. 35 Issue 2, p134 

    Dose-response of formoterol via pressurized metered-dose inhaler (pMDI) has not been determined in asthmatic pediatric patients aged 6 to <12 years. This study was designed to assess the bronchodilating dose-response of three formoterol pMDI doses in children with stable asthma aged 6 to <12...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics